Skip to main content

Table 3 Mean effective dose received by survivors and controls with proportion of survivors receiving 50 and 100 mSv in years 5 through 15 after diagnosis/referent dates, stratified by malignancy type

From: Patterns of diagnostic imaging and associated radiation exposure among long-term survivors of young adult cancer: a population-based cohort study

   Mean Effective Dose, mSv Survivors Receiving Effective Dose
   Dose, mSv n (%)
Malignancy Type n Survivors Controls 50 mSv 100 mSv
All Malignancies 20911 26.3 10.7 3333 (15.9) 1314 (6.3)
Breast 4581 34.4 13.0 909 (19.8) 386 (8.4)
Gynecologica 2782 19.6 11.2 308 (11.1) 120 (4.3)
Thyroid 2388 18.3 10.0 258 (10.8) 60 (2.5)
Melanoma 2088 14.9 9.9 166 (8.0) 60 (2.9)
Testicular 1390 23.4 7.8 241 (17.3) 57 (4.1)
NHL 1277 46.0 10.2 364 (28.5) 193 (15.1)
HL 1072 31.8 7.2 211 (19.7) 98 (9.1)
Urologic 895 31.6 11.2 175 (19.6) 76 (8.5)
Colorectal 785 26.4 12.1 140 (17.8) 50 (6.4)
Head & Neck 768 22.5 11.4 101 (13.2) 40 (5.2)
Brain 632 16.3 9.4 47 (7.4) 8 (1.3)
Bone & Soft-tissue 463 20.8 7.9 64 (13.8) 24 (5.2)
Chest & Lung 345 28.2 11.3 66 (19.1) 29 (8.4)
Leukemia 284 26.8 8.9 55 (19.4) 28 (9.9)
Upper GI 274 36.7 12.0 68 (24.8) 25 (9.1)
  1. aIncludes cervical, uterine and ovarian malignancies.
  2. Abbreviations: mSv, miliSieverts; NHL, non-Hodgkin lymphoma; HL, Hodgkin lymphoma; GI, gastrointestinal.